So Seel or one of the more scientific minds, since Leo and Dr Menon are eagerly awaiting the transfer of info on the pharmacokinetic analysis from the trial from DF, what in your opinion do you envision the next PR saying about his specific data? Should we expect any type of numeric specific data, or a more general top line review?